Phase 2 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard performance scale (Karnofsky index ≥80%) (confirm with trial site)
- People who have been diagnosed with a type of head and neck cancer called squamous cell carcinoma (HNSCC) — including cancers of the mouth, throat, or voice box — confirmed by a tissue sample
- People who have cancer that has spread to at least one lymph node in the neck
- People who are scheduled to have surgery to remove lymph nodes in the neck (neck dissection)
- People who have already had standard pre-surgery scans, including an MRI, a contrast CT scan, and a PET/CT scan using a tracer called 18F-FDG
- People who have provided written agreement to take part in the trial
Who may not be able to join:
- People who are known to be pregnant or who are currently breastfeeding
- People who experience claustrophobia (fear of enclosed spaces)
- People with severely reduced kidney function (confirm with trial site)
- People whose liver enzyme levels are more than five times above the normal upper limit
- People whose bilirubin levels are more than three times above the normal upper limit
- People with a low red blood cell count (haemoglobin below 8 g/dL)
- People with a low level of a type of white blood cell called neutrophils (below 1000/mm³)
- People with a low platelet count (below 75,000/µL)
- People who do not have a sufficient understanding of the language used in the trial, or who are otherwise unable to give consent or follow the trial procedures
- People who have chosen to exercise their right not to be informed about findings unrelated to their main condition that may be discovered during the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Niklaus Schaefer, MD, Centre Hospitalier Universitaire Vaudois
Phone: +41 21 314 4348
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
[68Ga]Ga-FAPI-46 PET/CT imaging results: tumor size; [68Ga]Ga-FAPI-46 PET/CT imaging results: tumor volume; [68Ga]Ga-FAPI-46 PET/CT imaging results: tumor SUVmax; [68Ga]Ga-FAPI-46 PET/CT imaging results: number of lesions; [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion site; [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion size; [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion volume; [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion SUVmax; [68Ga]Ga-FAPI-46 PET/CT imaging results: TNM tumor stage
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.